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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S131patients were treated with ACI or MACI (4 Carticel, 13 Hyalograft, 2 Cares)
and 25 patients were treated with MFX. The average age (SD) at surgery
was 32  12 years and the average Body Mass Index (BMI) was 26.4  4.2.
The average follow up duration was 66  38 months (11-168).
For clinical evaluation, the American Orthopedic Foot and Ankle Score
(AOFAS), the OSG-Score and the modiﬁed Cincinnati Score were obtained.
Results:We depicted signiﬁcant differences in the ACI/MACI group as well
as in the MFX group in all scores when compared to preoperative scores. In
the ACI/MACI group the AOFAS Score (52.16 vs. 86.16; p<0.01), the OSG-
Score (45.79 vs. 82.11; p<0.01) and the modiﬁed Cincinnati Score (3.0 vs.
7.0; p<0.01) showed a signiﬁcant increase. The MFX group demonstrated
a signiﬁcant increase in the AOFAS Score (41.92 vs. 80.92; p<0.01), the
OSG-Score (51.80 vs. 82.40; p<0.01) and the modiﬁed Cincinnati Score
(2.96 vs. 6.84; p<0.01).
Conclusions: According to our data, both ACI/MACI and MFX achieved
a comparable outcome at mid -term. But there is still a need for long-term
results to demonstrate the permanency of these results.
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OSTEOCHONDRAL AUTOGENOUS TRANSFER FOR SPONTANEOUS
OSTEONECROSIS OF THE MEDIAL FEMORAL CONDYLE OF THE KNEE
IN MIDDLE-AGED AND ELDERLY PATIENTS
H. Harada, M. Kobayashi, R. Arai, H. Tsukiyama. Faculty of Med., Kyoto Univ.,
Kyoto City, Japan
Purpose: Osteochondral autogenous transfer (OAT) became widespread
for the treatment of spontaneous osteonecrosis of the knee (SONK). And,
recently good results after OAT expand surgical indication to older patients
as well as to young patients. The purpose of this study was to evaluate
clinical outcome of OAT for SONK in middle-aged and elderly patients.
Methods: Ten patients were included who received only OAT for SONK
between July 2005 and September 2010, and whose age was more than 35
years old. Five was left knee. The average age at the time of OAT was 63.1
years (range 36-72 years). Diagnosis of all cases was done by MRI of the
knee. OAT was performed for those whose femorotibial angle (FTA) was
under 180 or whose mechanical axis (Mikulics line) passed lateral side of
the lesion in standing plain radiographs. Those who underwent re-align-
ment surgery such as HTO were excluded. Capsulotomy was performed by
mini-open medial parapatellar approach. Osteochondral plugs were har-
vested and transferred from ipsilateral trochlear ridge to the lesion. Post-
operative rehabilitaion included non-weight-bearing for three weeks,
partial weight-bearing for 4 weeks thereafter, and full weight-bearing was
allowed after 7 weeks post-surgery.
Result: Mean preoperative Lysholm score was 60.3 points (range 49-73
points). Mean postoperative Lysholm score at one year after operation was
92.5 points (range 85-100 points). All patients became to be able to sit
straight in Japanese style. MR images at one year after operation showed
that the transferred osteochondral plugs were same intensity as peripheral
cancellous bone meaning that the plugs were well integrated. In one case,
MRI showed T1 low and T2 high intensity in part of osteochondral plugs
indicating poor integration. Lysholm score at one year after operation was
90 points in that case.
Conclusion: It is assumed that less ability of cartilage repair and degen-
erative change of the donor site could affect postoperative outcome of OAT
in elderly patients. If chondral lesion is localized and there is no mal-
alignment in the knee, OAT is an option for treatment of SONK even in
middle-aged and elderly patients.
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OSTEOCHONDRAL DEFECT REPAIR USING A NOVEL NATURALLY
DERIVED BIOMATERIAL SCAFFOLD
G.J. Breur, D.A. Dickerson, R.L. Johnson, P.W. Snyder, E.A. Nauman. Purdue
Univ., West Lafayette, IN, USA
Purpose: This study was intended to determine the biocompatibility and
efﬁcacy of osteochondral repair using a novel naturally derived biomaterial
scaffold.
Methods: Scaffolds were derived from porcine cancellous bone (vertebral
bodies) obtained from a local abattoir. Bone cylinders (7mm diameter,10mm length) were machined, and marrow spaces were cleaned and
defatted. Scaffolds were created by regional demineralization, resulting in
a porous cylindrical scaffold with an 8mm mineralized end and a 2mm
demineralized end.
Six healthy mature ewes, free of lameness and radiographic evidence of
stiﬂe (knee) pathology were included in the study. Sheep were pre-
medicated with diazepam, induced with pentothal, and maintained on
isoﬂurane and oxygen using endotracheal intubation and a ventilator. The
stiﬂe joint was entered using a medial and lateral parapatellar approach.
Three 6 mm diameter and 10 mm deep holes were created using
commercially available surgical equipment. Defects were created on the
distal trochlea (non-weightbearing) and the condyles (weightbearing).
Defects were randomly assigned as scaffold-treated or untreated (control).
Scaffolds were press-ﬁt into the defects. The procedure was repeated on
the contralateral limb at 8 weeks before euthanasia.
Ewes were euthanized 6 months after the ﬁrst surgery. First the stiﬂes and
then each defect and its surroundings were isolated. The proximal half of
the specimen was used for mechanical testing; the distal half was used for
histological evaluation. Histological specimens were decalciﬁed and
embedded in parafﬁn; sections were cut at 5mm and stained (with
hematoxylin & eosin, safranin-o/fast green, type I collagen or type II
collagen). H&E and SOFG slides were analyzed and scored according to the
ICRS II scoring system. A semi-quantitative analysis of collagen type within
the repair tissue was performed using digital image analysis. From each
specimen, 3mm-diameter cylinders were obtained from normal and repair
cartilage for mechanical testing. Conﬁned compression testing was per-
formed to measure aggregate modulus (HA).
Results: Histological analysis - All scaffold-treated defects were covered
with hyaline-like cartilagewith very littleﬁbrous connective tissue. In twoof
the scaffold treated defects, the calciﬁed region of the scaffold was sur-
rounded byan inﬂammatory responsewithﬁbrous connective tissue. ICRS II
scores trended higher for scaffold-treated defects in most parameters,
including the Overall Assessment (Control: 49.6% 28.9%, Scaffold-Treated:
73.2%  10.1%). Both scaffold treated defects and control defects had strong
Type II collagen staining. Scaffold treated defects demonstrated signiﬁcantly
lower Type I collagen content, indicating a lower ﬁbrous tissue character.
Mechanical Properties - The average aggregate modulus of normal carti-
lage tissue was measured at 1300 400 kPa. The aggregate modulus in the
control group was 732  134 kPa, nearly signiﬁcantly different from the
normal cartilage (p ¼ 0.062). The aggregate modulus of the scaffold
repaired group was 988  133 kPa (p ¼ 0.536).
Conclusions: A novel natural biomaterial scaffold was developed from
cancellous bone with a continuous interface connecting soft and hard
tissue regions, replicating the normal graded interface between cartilage
and bone. Implantation into osteochondral defects in sheep stiﬂe joints
produced repair tissue with biochemical and biomechanical properties
approaching those of normal cartilage. This scaffold may have applications
in cartilage repair for backﬁll of OATS autograft or primary repair of
osteochondral defects.
252
AETIOLOGY OF EXPERIMENTALLY INDUCED OSTEOARTHRITIS OF THE
KNEE; BIOMECHANICAL OR BIOCHEMICAL FACTORS?
K. Wiegant, M. Beekhuizen, S.C. Mastbergen, A.D. Barten - van
Rijbroek, L.B. Creemers, D.B. Saris, F.P. Lafeber. Univ. Med. Ctr. Utrecht,
Utrecht, Netherlands
Purpose: Disturbance of joint homeostasis, due to several risk factors, can
result in osteoarthritis (OA). In the present study we investigated the role of
biomechanical loading and biochemical joint homeostasis in the develop-
ment of osteoarthritis, in an experimental caprine model of joint damage.
Methods: In nine skeletallymature femalemilk goats, cartilage damagewas
introduced in the right stiﬂe joint according to the Groove model. Grooves
were made with a K-wire with a bend tip, only on the medial femoral
condyle and maximally 0.5mm deep.The left stiﬂe joint served as a control.
After 20 weeks the goats were euthanized and the cartilage and synovial
tissue was analyzed on macroscopical, histological (both OARSI goat score)
and biochemical (proteoglycan (PG) turnover) OA characteristics.
Results: Macroscopic analysis showed a signiﬁcant increase in the OARSI
goat cartilage score for both the femoral and tibial experimental medial
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+42.9% p<0.04 respectively). No effect on the ungrooved lateral
compartment was seen. The histological analysis of the cartilage corrob-
orated these results. A signiﬁcant increase in the OARSI score for the
experimental medial compartment (+225% p<0.001 and +81,7% p<0.006,
respectively for femur and tibia) was seen. Biochemical analysis showed
a decreased PG content in the medial experimental compartment
compared to control (femur -12.09% p¼0.038 and tibia -7.32% p¼0.031).
There was a slight increase in synovial inﬂammation in the experimental
joint (p<0.003). For all previous mentioned analyses, no changes in the
experimental lateral compartment or the control joint were found.
Conclusions: The present study shows clearly that the development of
joint damage is much more dependent on the biomechanical component,
since all detectable damage is in the medial compartment. Joint homeo-
stasis is disturbed, indicated by moderate synovial inﬂammation.
However, this did not lead to generalised OA in this time period.
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REDIFFERENTIATION OF HUMAN DEDIFFERENTIATED CHONDROCYTES
: AN INNOVATIVE COMBINATION FOR THE CELL THERAPY OF
ARTICULAR CARTILAGE
F. Legendre 1, D. Ollitrault 1, M. Hervieu 1, C. Bauge 1, L. Maneix 1,
H. Benateau 1, E. Renard 1, S. Leclercq 2, H. Chajra 3, C. Drougard 1,
M. Briand 4, L. Poulain 4, F. Mallein-Gerin 5, K. Boumediene 1,
P. Galera 1, M. Demoor 1. 1MILPAT - Univ. of Caen/Basse-Normandie, CAEN,
France; 2Clinic St Martin, CAEN, France; 3 Symatèse Biomatériaux, Chaponost,
France; 4BIOTICLA - Univ. of Caen/Basse-Normandie, CAEN, France; 5 Lab.
Biology and Engineering of Cartilage - CNRS FRE 3310, LYON, France
Purpose: Since two decades, Autologous Chondrocytes Implantation (ACI)
constitutes a therapeutic alternative in cartilage healing to return back to
a functionally tissue after trauma or age related degeneration. Beyond the
clinical aspect with its encouraging results, themajor goal conditioning the
success of ACI is to obtain a hyaline neo-cartilage with redifferentiated and
phenotypically stabilized chondrocytes. Indeed, the inescapable ampliﬁ-
cation step dedifferentiates chondrocytes, which synthesize a type I non-
functional collagen to the detriment of type II collagen and aggrecan
phenotypic markers. To restart an active metabolism typical of a hyaline
matrix, we developped a clinical suitable process which combine relevant
physicochimic factors for chondrocytes culture such as collagen scaffold,
BMP-2 and IGF-I as chondrogenic factors, physioxic conditions and tran-
sient RNA interference targeting COL1A1 and PSBA (a so-called protein
implied in BMP-2 activity and matrix regulation).
Methods: Dedifferentiated Human Articular Chondrocytes (HAC) from
macroscopically healthy zones but inﬂammatory environment of femoral
heads from patients undergoing joint arthroplasty (age range 52-83) were
cultured in type I collagen sponges, under low oxygen tension, and incu-
bated with BMP-2/IGF-I. siRNAs were used to counteract type I collagen
and to sustain chondrogenic factors activity. An extensive analysis at gene
and protein levels relevant to differentiated, dedifferentiated and hyper-
trophic chondrocyte phenotypes was achieved and used to calculate the
differentiation index corresponding to the ratio of COL2A1 mRNA/COL1A1
mRNA completed by the ratio of type IIB collagen/type IIA collagenmRNAs.
Finally, we have evaluated the behavior of such differentiated chon-
drocytes in vivo, by subcutaneous implantation in the nude mouse model
followed by immunohistochemistry analysis.
Results: Collagen sponges support metabolic activity of viable rediffer-
entiated chondrocytes expressing type II B collagen and aggrecan, without
sign of hypertrophy. The best differentiated phenotype proﬁle was
obtained after 7 days in culture with BMP-2 which enhanced transcription
activity of COL2A1 gene by its speciﬁc enhancer region. The sustained
BMP-2 action by siRNA treatment and COL1A1 down-regulation improved
the differentiation index of chondrocytes, which synthesize a hyaline like-
matrix 28 days after subcutaneous implantation.
Conclusions: HAC phenotype can be restarted and stabilized by this
clinically suitable process with a biodegradable scaffold allowing the
maintenance of chondrocyte characteristics and with a less invasive
surgical method (patent request N10 57683). This study will allow to
develop newmethods for autologous chondrocyte implantation in human.254
GOOD MANUFACTURING PRACTICES IN AUTOLOGOUS CHONDROCYTE
IMPLANTATION: THE EXPERIENCE IN A PUBLIC HOSPITAL
L. Roseti, P.M. Fornasari, A. Maso, E. Storni, M. Serra, F. Canella, A. Tosi,
C. Munno, B. Grigolo, A. Bassi. Istituto Ortopedico Rizzoli, Bologna, Italy
Purpose: Autologous chondrocyte implantation (ACI) is a widely diffused
technique utilized for the treatment of articular cartilage damages. In vitro
expanded chondrocytes for ACI procedure are considered advanced therapy
medicinal products (ATMPs), as deﬁned by the European Regulation.
Consequently, it is mandatory that they have to be manufactured in accor-
dance with the “speciﬁc medicinal rules” named Good Manufacturing
Practices (GMPs) and in dedicated environments built as real “pharmaceu-
tical factories”. This study describes the GMPs development and character-
ization (validation) of chondrocyte-based medicinal products to be used
in ACI.
Methods: Chondrocyte cultures were carried on in a production facility
located in a Public Hospital and including clean rooms of different classi-
ﬁcation up to A in B work places, according to current GMPs (see ﬁgure).
After informed consent, a cartilage biopsy was harvested from a non-
bearing area of the knee of ten patients undergoing ACI. The tissues were
enzymatically digested to isolate chondrocytes. Primary cultures were
expanded in monolayer up to 3-4 passages and cells seeded at deﬁned
density onto matrices derived from collagen I/III (bi-dimensional). Engi-
neered constructs were analyzed for the following parameters: sterility
(microbiological control, Mycoplasma and endotoxins), cell number,
viability and the expression of different phenotypic markers. Microbio-
logical control was performed using an automated system allowing to
reveal the presence of aerobic, anaerobic bacteria and fungi. Highly-
sensitive Real Time Quantitative DNA PCR technology was the method
used for detecting contaminating Mycoplasma. Bacterial endotoxin assays
were performed by quantitative Lymulus Amebocyte Lysate (LAL). Cell
number and viability were evaluated with both an automated cell counter
and the MTT test. Markers typical for hyaline cartilage (collagen II and
aggrecan), ﬁbro-cartilage (collagen I) and bone tissue (osteocalcin) were
evaluated by immuno-histochemical analyses.
Results: Engineered chondrocytes were free of contamination from
aerobic and anaerobic bacteria, fungi, Mycoplasma and endotoxins, viable
(90-98%). The phenotipic analysis revealed that chondrocytes were able to
express the typical hyaline cartilage molecules, collagen II and proteogli-
cans. Collagen I and osteocalcin, markers of ﬁbroblasts a bone, respectively
were not present.
Conclusions: Our results evidentiated the ability to manufacture chon-
drocyte-based medicinal products that are sterile, viable, phenotypically
stable and therefore suitable for ACI application. After this initial validation,
the cultures of 100 patients undergoing ACI were treated in our Cell Factory.Ă
